AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo
RegulatoryapprovedRinvoqPositive
AI Analysis
Summary
AbbVie received EU regulatory clearance for Rinvoq as the first systemic treatment for non-segmental vitiligo. This approval represents a significant milestone in treating the autoimmune skin condition.
Outcome Details
EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo
Importance:8/10
Sentiment:
0.85
regulatory approvalEU clearancefirst-in-classvitiligosystemic treatment
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on July 29, 2026 8:14 AM